Ignite Creation Date:
2024-05-06 @ 8:29 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06398587
Status:
WITHDRAWN
Last Update Posted:
2024-05-03
First Post:
2024-04-30
Brief Title:
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma
Sponsor:
OHSU Knight Cancer Institute
Organization:
OHSU Knight Cancer Institute
Organization Data
Organization:
OHSU Knight Cancer Institute
Class:
OTHER
Study ID:
STUDY00026545
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
OHSU Knight Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Charles D Lopez
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
OHSU Knight Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Oregon Health and Science University | OTHER |